Townsend & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $223K | Buy |
8,993
+4
| +0% | +$105 | 0.02% | 109 |
|
|
2026
Q1 | $241K | Buy |
8,989
+3
| +0% | +$80 | 0.02% | 108 |
|
|
2025
Q4 | $233K | Buy |
8,986
+202
| +2% | +$5.09K | 0.02% | 105 |
|
|
2025
Q3 | $215K | Sell |
8,784
-87
| -1% | -$2.15K | 0.02% | 107 |
|
|
2025
Q2 | $220K | Sell |
8,871
-1,001
| -10% | -$23.3K | 0.02% | 99 |
|
|
2025
Q1 | $218K | Sell |
9,872
-338
| -3% | -$8.85K | 0.02% | 94 |
|
|
2024
Q4 | $272K | Hold |
10,210
| – | – | 0.03% | 94 |
|
|
2024
Q3 | $295K | Buy |
10,210
+404
| +4% | +$11.8K | 0.03% | 89 |
|
|
2024
Q2 | $302K | Buy |
9,806
+6
| +0.1% | +$165 | 0.03% | 87 |
|
|
2024
Q1 | $258K | Buy |
9,800
+5
| +0.1% | +$139 | 0.03% | 88 |
|
|
2023
Q4 | $277K | Sell |
9,795
-209
| -2% | -$6.32K | 0.03% | 89 |
|
|
2023
Q3 | $301K | Sell |
10,004
-10,092
| -50% | -$357K | 0.06% | 86 |
|
|
2023
Q2 | $745K | Sell |
20,096
-396
| -2% | -$15.4K | 0.19% | 85 |
|
|
2023
Q1 | $797K | Sell |
20,492
-27,261
| -57% | -$1.18M | 0.32% | 78 |
|
|
2022
Q4 | $2.1M | Sell |
47,753
-457
| -0.9% | -$21.9K | 1.04% | 36 |
|
|
2022
Q3 | $2.28M | Buy |
48,210
+6,685
| +16% | +$325K | 1.05% | 31 |
|
|
2022
Q2 | $2.2M | Buy |
+41,525
| New | +$2.12M | 1.02% | 25 |
|
|
2021
Q1 | – | Sell |
-36,128
| Closed | -$1.33M | – | 84 |
|
|
2020
Q4 | $1.33M | Sell |
36,128
-4,362
| -11% | -$160K | 0.97% | 52 |
|
|
2020
Q3 | $1.41M | Sell |
40,490
-13,026
| -24% | -$457K | 1.11% | 46 |
|
|
2020
Q2 | $1.66M | Sell |
53,516
-6,642
| -11% | -$226K | 1.39% | 29 |
|
|
2020
Q1 | $1.92M | Buy |
60,158
+166
| +0.3% | +$5.66K | 1.99% | 10 |
|
|
2019
Q4 | $2.22M | Sell |
59,992
-2,510
| -4% | -$89.4K | 1.94% | 10 |
|
|
2019
Q3 | $2.1M | Buy |
62,502
+12,919
| +26% | +$470K | 2.01% | 11 |
|
|
2019
Q2 | $2.09M | Buy |
49,583
+301
| +0.6% | +$12K | 1.59% | 19 |
|
|
2019
Q1 | $1.99M | Buy |
+49,282
| New | +$1.97M | 2% | 21 |
|
|
2018
Q4 | – | Sell |
-284
| Closed | -$12K | – | 126 |
|
|
2018
Q3 | $12K | Buy |
284
+3
| +1% | +$115 | 0.01% | 129 |
|
|
2018
Q2 | $10K | Sell |
281
-131
| -32% | -$4.48K | 0.01% | 129 |
|
|
2018
Q1 | $14K | Sell |
412
-44,059
| -99% | -$1.51M | 0.01% | 124 |
|
|
2017
Q4 | $1.53M | Buy |
+44,471
| New | +$1.52M | 1.3% | 27 |
|
Other funds holding PFE
Townsend & Associates's PFE Position: Q2 2026 in Review
Townsend & Associates increased its Pfizer (PFE) stake by 0.04% in Q2 2026, buying an estimated $105 and bringing the position to 8,993 shares worth $223K. The position accounts for 0.02% of the portfolio, ranked #109.
Townsend & Associates first reported a position in PFE in Q4 2017 and has held it in 29 quarters since. The position peaked at $2.28M in Q3 2022. 2,832 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Townsend & Associates held 8,993 shares of Pfizer worth $223K as of Q2 2026.
- Townsend & Associates bought 4 Pfizer shares in Q2 2026, an estimated $105.
- Pfizer made up 0.02% of Townsend & Associates's portfolio in Q2 2026, its #109 holding.
- Townsend & Associates first reported a position in Pfizer in Q4 2017 and has held it in 29 quarters since.
- Townsend & Associates's Pfizer position peaked at $2.28M in Q3 2022.
- 2,832 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Townsend & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.